Abdominal obesity, insulin resistance, metabolic syndrome and cholesterol homeostasis

PharmaNutrition

Volumn 1, Issue 4, 2013, Pages 130-136

  Taverne, Femke ^a   Richard, Caroline ^a   Couture, Patrick ^a   Lamarche, Benoît ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Abdominal obesity; Cholesterol homeostasis; Insulin resistance; Metabolic syndrome

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RADIOISOTOPE;

ABDOMINAL OBESITY; CAPILLARY GAS CHROMATOGRAPHY; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; INTESTINE ABSORPTION; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; ISOTOPE LABELING; LIPID ABSORPTION; LIPID ANALYSIS; MASS FRAGMENTOGRAPHY; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84888436865     PISSN: 22134344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phanu.2013.07.003     Document Type: Review

References (75)

1. Allender S., Scarborough P., Peto V., Rayner M., Leal J., Luengo-Fernandez R., et al. European cardiovascular disease statistics 2008 2008.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
3. Vaartjes I., Van Dis I., Visseren F.L.J., Bots M.L. Sterfe aan hart-en vaatziekten in Nederland. Hart Bulletin 2010, 41:19-23.
4. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
5. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777-780.
6. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Journal of the American College of Cardiology 2008, 52:1769-1781.
7. Wilt T.J., Bloomfield H.E., MacDonald R., Nelson D., Rutks I., Ho M., et al. Effectiveness of statin therapy in adults with coronary heart disease. Archives of Internal Medicine 2004, 164:1427-1436.
8. Lamarche B., Lewis G.F. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol. Canadian Journal of Cardiology 1998, 14:841-851.
9. Lamarche B., Lemieux I., Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes & Metabolism 1999, 25:199-211.
10. St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Bernard P.M., Despres J.P., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001, 104:2295-2299.
11. St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.P., Lamarche B. Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. American Journal of Cardiology 2006, 97:997-1001.
12. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
13. Sniderman A.D., St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.P., Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. American Journal of Cardiology 2003, 91:1173-1177.
14. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
15. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation Cardiovascular Quality and Outcomes 2011, 4:337-345.
16. Mottillo S., Filion K.B., Genest J., Joseph L., Pilote L., Poirier P., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. Journal of the American College of Cardiology 2010, 56:1113-1132.
17. Bergman R.N., Kim S.P., Hsu I.R., Catalano K.J., Chiu J.D., Kabir M., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. American Journal of Medicine 2007, 120:S3-S8. [discussion S29-32].
18. Levesque J., Lamarche B. The metabolic syndrome: definitions, prevalence and management. Journal of Nutrigenetics and Nutrigenomics 2008, 1:100-108.
19. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
20. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA: Journal of the American Medical Association 2002, 287:356-359.
21. Despres J.P. Is visceral obesity the cause of the metabolic syndrome. Annals of Medicine 2006, 38:52-63.
22. Kwon C.H., Kim B.J., Kim B.S., Kang J.H. Low-density lipoprotein cholesterol to apolipoprotein B ratio is independently associated with metabolic syndrome in Korean men. Metabolism: Clinical and Experimental 2011, 60:1136-1141.
23. Lamarche B., St-Pierre A.C. Features of the metabolic syndrome and the risk of cardiovascular disease. Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals 2005, 10(Suppl. 1):S37-S43.
24. Gylling H., Hallikainen M., Kolehmainen M., Toppinen L., Pihlajamaki J., Mykkanen H., et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. Translational Research: Journal of Laboratory and Clinical Medicine 2007, 149:310-316.
25. Simonen P., Gylling H., Howard A.N., Miettinen T.A. Introducing a new component of the metabolic syndrome: low cholesterol absorption. American Journal of Clinical Nutrition 2000, 72:82-88.
26. Matthan N.R., Giovanni A., Schaefer E.J., Brown B.G., Lichtenstein A.H. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. Journal of Lipid Research 2003, 44:800-806.
27. Matthan N.R., Pencina M., LaRocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., et al. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. Journal of Lipid Research 2009, 50:1927-1935.
28. Santosa S., Varady K.A., AbuMweis S., Jones P.J. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist. Life Sciences 2007, 80:505-514.
29. Liscurn L., Dennis E., Vance J.E.V. Chapter 15 cholesterol biosynthesis. New comprehensive biochemistry 2002, 409-431. Elsevier Science & Technology, Amsterdam.
30. Dietschy J.M. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. American Journal of Clinical Nutrition 1997, 65:1581S-1589S.
31. Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clinical Pharmacokinetics 1997, 32:403-425.
32. Descamps O.S., De Sutter J., Guillaume M., Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. Atherosclerosis 2011.
33. Miettinen T.A., Strandberg T.E., Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:1340-1346.
34. Jones P.J., Raeini-Sarjaz M., Ntanios F.Y., Vanstone C.A., Feng J.Y., Parsons W.E. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. Journal of Lipid Research 2000, 41:697-705.
35. Vanstone C.A., Raeini-Sarjaz M., Parsons W.E., Jones P.J. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. American Journal of Clinical Nutrition 2002, 76:1272-1278.
36. Stellaard F., Kuipers F. Assessment of modes of action and efficacy of plasma cholesterol-lowering drugs: measurement of cholesterol absorption, cholesterol synthesis and bile acid synthesis and turnover using novel stable isotope techniques. Current Drug Targets Immune, Endocrine and Metabolic Disorders 2005, 5:209-218.
37. Matthan N.R., Lichtenstein A.H. Approaches to measuring cholesterol absorption in humans. Atherosclerosis 2004, 174:197-205.
38. Bosner M.S., Ostlund R.E., Osofisan O., Grosklos J., Fritschle C., Lange L.G. Assessment of percent cholesterol absorption in humans with stable isotopes. Journal of Lipid Research 1993, 34:1047-1053.
39. Miettinen T.A., Tilvis R.S., Kesaniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. American Journal of Epidemiology 1990, 131:20-31.
40. Nissinen M.J., Gylling H., Miettinen T.A. Responses of surrogate markers of cholesterol absorption and synthesis to changes in cholesterol metabolism during various amounts of fat and cholesterol feeding among healthy men. British Journal of Nutrition 2008, 99:370-378.
41. Escurriol V., Cofan M., Moreno-Iribas C., Larranaga N., Martinez C., Navarro C., et al. Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort. Journal of Lipid Research 2010, 51:618-624.
42. Mackay D.S., Jones P.J. Plasma noncholesterol sterols: current uses, potential and need for standardization. Current Opinion in Lipidology 2012, 23:241-247.
43. Demonty I., Ras R.T., van der Knaap H.C., Duchateau G.S., Meijer L., Zock P.L., et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. Journal of Nutrition 2009, 139:271-284.
44. Lees A.M., Mok H.Y., Lees R.S., McCluskey M.A., Grundy S.M. Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis 1977, 28:325-338.
45. Salen G., Ahrens E.H., Grundy S.M. Metabolism of beta-sitosterol in man. Journal of Clinical Investigation 1970, 49:952-967.
46. Miettinen T.A., Gylling H., Nissinen M.J. The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2011, 21:765-769.
47. Genser B., Silbernagel G., De Backer G., Bruckert E., Carmena R., Chapman M.J., et al. Plant sterols and cardiovascular disease: a systematic review and meta-analysis. European Heart Journal 2012, 33:444-451.
48. Weingartner O., Lutjohann D., Vanmierlo T., Muller S., Gunther L., Herrmann W., et al. Markers of enhanced cholesterol absorption are a strong predictor for cardiovascular diseases in patients without diabetes mellitus. Chemistry and Physics of Lipids 2011, 164:451-456.
49. Fassbender K., Lutjohann D., Dik M.G., Bremmer M., Konig J., Walter S., et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-the LASA study. Atherosclerosis 2008, 196:283-288.
50. Strandberg T.E., Gylling H., Tilvis R.S., Miettinen T.A. Serum plant and other noncholesterol sterols, cholesterol metabolism and 22-year mortality among middle-aged men. Atherosclerosis 2010, 210:282-287.
51. Windler E., Zyriax B.C., Kuipers F., Linseisen J., Boeing H. Association of plasma phytosterol concentrations with incident coronary heart disease data from the CORA study, a case-control study of coronary artery disease in women. Atherosclerosis 2009, 203:284-290.
52. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
53. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998, 316:1127-1130.
54. Matthan N.R., Resteghini N., Robertson M., Ford I., Shepherd J., Packard C., et al. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. Journal of Lipid Research 2010, 51:202-209.
55. Lupattelli G., De Vuono S., Mannarino E. Patterns of cholesterol metabolism: pathophysiological and therapeutic implications for dyslipidemias and the metabolic syndrome. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2011, 21:620-627.
56. Hernandez-Mijares A., Banuls C., Jover A., Sola E., Bellod L., Martinez-Triguero M.L., et al. Low intestinal cholesterol absorption is associated with a reduced efficacy of phytosterol esters as hypolipemic agents in patients with metabolic syndrome. Clinical Nutrition 2011, 30:604-609.
57. Ooi E.M., Ng T.W., Chan D.C., Watts G.F. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diabetes Research and Clinical Practice 2009, 85:310-316.
58. Cofan M., Escurriol V., Garcia-Otin A.L., Moreno-Iribas C., Larranaga N., Sanchez M.J., et al. Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD 2010, 21:651-657.
59. Nunes V.S., Leanca C.C., Panzoldo N.B., Parra E., Cazita P.M., Nakandakare E.R., et al. HDL-C concentration is related to markers of absorption and of cholesterol synthesis: study in subjects with low vs. high HDL-C. Clinica Chimica Acta: International Journal of Clinical Chemistry 2011, 412:176-180.
60. Scaglione R., Di Chiara T., Cariello T., Licata G. Visceral obesity and metabolic syndrome: two faces of the same medal. Internal and Emergency Medicine 2010, 5:111-119.
61. Gylling H., Hallikainen M., Pihlajamaki J., Simonen P., Kuusisto J., Laakso M., et al. Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study. Journal of Lipid Research 2010, 51:2422-2427.
62. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine: A Journal of the British Diabetic Association 2006, 23:469-480.
63. Linton M.F., Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications. American Journal of Cardiology 2003, 92:19i-26i.
64. Arsenault B.J., Lemieux I., Despres J.P., Wareham N.J., Luben R., Kastelein J.J., et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. European Heart Journal 2007, 28:2770-2777.
65. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men. Circulation 2000, 102:179-184.
66. Trayhurn P. Adipocyte biology. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 2007, 8(Suppl. 1):41-44.
67. Peltola P., Pihlajamaki J., Koutnikova H., Ruotsalainen E., Salmenniemi U., Vauhkonen I., et al. Visceral obesity is associated with high levels of serum squalene. Obesity 2006, 14:1155-1163.
68. Lupattelli G., Pirro M., Mannarino M.R., Siepi D., Roscini A.R., Schillaci G., et al. Visceral fat positively correlates with cholesterol synthesis in dyslipidaemic patients. European Journal of Clinical Investigation 2012, 42:164-170.
69. Simonen P., Kotronen A., Hallikainen M., Sevastianova K., Makkonen J., Hakkarainen A., et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. Journal of Hepatology 2011, 54:153-159.
70. Hajer G.R., van Haeften T.W., Visseren F.L. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European Heart Journal 2008, 29:2959-2971.
71. Simonen P.P., Gylling H.K., Miettinen T.A. Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 2002, 25:1511-1515.
72. Hoenig M.R., Sellke F.W. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis 2010, 211:260-265.
73. Pihlajamaki J., Gylling H., Miettinen T.A., Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. Journal of Lipid Research 2004, 45:507-512.
74. Paramsothy P., Knopp R.H., Kahn S.E., Retzlaff B.M., Fish B., Ma L., et al. Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. American Journal of Clinical Nutrition 2011, 94:1182-1188.
75. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 2002, 109:1125-1131.